{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T05:44:32Z","timestamp":1788327872398,"version":"build-2803163510"},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Lessons Learned<\/jats:title>\n                  <jats:p>Despite U.S. Food and Drug Administration approval to reduce alopecia, data on efficacy of scalp cooling in Black patients with cancer are limited by lack of minority representation in prior clinical trials. Scalp cooling devices may have less efficacy in Black patients; additional studies are required to explore the possible causes for this, including hair texture and cap design.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The Paxman scalp cooling (SC) device is U.S. Food and Drug Administration (FDA)-approved for prevention of chemotherapy-induced alopecia. Studies report 50%\u201380% success rates and high patient satisfaction, yet there have been no studies of SC in Black patients. We conducted a phase II feasibility study of Paxman SC with a planned enrollment of 30 Black patients receiving chemotherapy for stage I\u2013III breast cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Black patients who planned to receive at least four cycles of chemotherapy with non-anthracycline (NAC) or anthracycline (AC) regimens were eligible. Alopecia was assessed by trained oncology providers using the modified Dean scale (MDS) prior to each chemotherapy session. Distress related to alopecia was measured by the Chemotherapy Alopecia Distress Scale (CADS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Fifteen patients enrolled in the intervention before the study was closed early because of lack of efficacy. Median MDS and CADS increased after SC, suggesting increased hair loss (p &amp;lt; .001) and alopecia distress (p = .04). Only one participant was successful in preventing significant hair loss; the majority stopped SC before chemotherapy completion because of grade 3 alopecia (&amp;gt;50% hair loss).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>SC may not be efficacious in preventing alopecia in Black women. Differences in hair thickness, hair volume, and limitations of cooling cap design are possible contributing factors.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/onco.13690","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T13:34:52Z","timestamp":1611927292000},"page":"292-e548","source":"Crossref","is-referenced-by-count":23,"title":["Does Scalp Cooling Have the Same Efficacy in Black Patients Receiving Chemotherapy for Breast Cancer?"],"prefix":"10.1093","volume":"26","author":[{"given":"Asma","family":"Dilawari","sequence":"first","affiliation":[{"name":"MedStar Washington Hospital Center, Washington Cancer Institute, Lombardi Comprehensive Cancer Center, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Gallagher","sequence":"additional","affiliation":[{"name":"MedStar Washington Hospital Center, Washington Cancer Institute, Lombardi Comprehensive Cancer Center, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Princess","family":"Alintah","sequence":"additional","affiliation":[{"name":"MedStar Health Research Institute, Washington Cancer Institute, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami","family":"Chitalia","sequence":"additional","affiliation":[{"name":"MedStar Washington Hospital Center, Washington Cancer Institute, Lombardi Comprehensive Cancer Center, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Tiwari","sequence":"additional","affiliation":[{"name":"MedStar Washington Hospital Center, Washington Cancer Institute, Lombardi Comprehensive Cancer Center, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Paxman","sequence":"additional","affiliation":[{"name":"Paxman Scalp Cooling, Huddersfield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucile","family":"Adams-Campbell","sequence":"additional","affiliation":[{"name":"Georgetown University, Office of Minority Health and Cancer Prevention and Control, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiranjeev","family":"Dash","sequence":"additional","affiliation":[{"name":"Georgetown University, Office of Minority Health and Cancer Prevention and Control, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,2,17]]},"reference":[{"key":"2021122512040782800_onco13690-bib-0001","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1200\/JOP.17.00038","article-title":"Management of chemotherapy-induced alopecia with scalp cooling","volume":"14","author":"Kruse","year":"2018","journal-title":"J Oncol Pract"},{"key":"2021122512040782800_onco13690-bib-0002","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jama.2016.20939","article-title":"Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer: The SCALP randomized clinical trial","volume":"317","author":"Nangia","year":"2017","journal-title":"JAMA"},{"key":"2021122512040782800_onco13690-bib-0003","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s00520-018-4432-6","article-title":"Prolonging the duration of post-infusion scalp cooling in the prevention of anthracycline-induced alopecia: A randomised trial in patients with breast cancer treated with adjuvant chemotherapy","volume":"27","author":"Komen","year":"2019","journal-title":"Support Care Cancer"},{"key":"2021122512040782800_onco13690-bib-0004","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3109\/0284186X.2012.658966","article-title":"Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients - Results of the Dutch Scalp Cooling Registry","volume":"51","author":"Hurk","year":"2012","journal-title":"Acta Oncologica"},{"key":"2021122512040782800_onco13690-bib-0005","first-page":"S0190","article-title":"Geographic disparities in access to scalp cooling for the prevention of chemotherapy-induced alopecia in the United States","volume":"31171\u201331173","author":"Singer","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2021122512040782800_onco13690-bib-0006","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1056\/NEJM197912273012605","article-title":"Prevention of doxorubicin-induced hair loss with scalp hypothermia","volume":"301","author":"Dean","year":"1979","journal-title":"N Engl J Med"},{"key":"2021122512040782800_onco13690-bib-0007","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s10549-019-05169-0","article-title":"The effect of scalp cooling on CIA-related quality of life in breast cancer patients: A systematic review","volume":"175","author":"Marks","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"2021122512040782800_onco13690-bib-0008","first-page":"5","article-title":"Chemotherapy-induced hair loss","volume":"15","author":"Tr\u00fceb","year":"2010","journal-title":"Skin Therapy Lett"},{"key":"2021122512040782800_onco13690-bib-0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.breast.2018.04.012","article-title":"Scalp cooling successfully prevents alopecia in breast cancer patients undergoing anthracycline\/taxane-based chemotherapy","volume":"40","author":"Vasconcelos","year":"2018","journal-title":"Breast"},{"key":"2021122512040782800_onco13690-bib-0010","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s10549-017-4185-9","article-title":"Scalp cooling with adjuvant\/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: Systematic review and meta-analysis","volume":"163","author":"Rugo","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"2021122512040782800_onco13690-bib-0011","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/annonc\/mdt476","article-title":"Development and validation of chemotherapy-induced Alopecia Distress Scale (CADS) for breast cancer patients","author":"Cho","year":"2014","journal-title":"Ann Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13690","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13690","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/4\/292\/41923405\/oncolo_26_4_292.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/4\/292\/41923405\/oncolo_26_4_292.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T12:05:54Z","timestamp":1640433954000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/4\/292\/6445553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,17]]},"references-count":11,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,2,17]]},"published-print":{"date-parts":[[2021,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13690","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4,1]]},"published":{"date-parts":[[2021,2,17]]}}}